| Miebo (U.S.N.L.M.) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dosing | One drop QID | ||||||||||||||||||
| Chem Specs | 100% perfluorohexyloctane | ||||||||||||||||||
| Quantities | 3 mL (in 5ml dropper tip bottle)
| Cost |
$772.00 |
Class |
Semi-fluorinated alkane (aliphatic hydrocarbon) |
Action |
Forms amphiphilic, physiologically inert monolayer which reduces evaporation. |
Usage |
Indicated for the treatment of dry eye disease.
|
| 1-3% report blurred vision and/or conjunctival redness. |
Contraindications |
None |
Pediatric use |
Safety and efficacy not established in pediatric patients below the age of 18.
|
Pregnancy |
No adequate and well controlled studies with MIEBO in pregnant women. |
No evidence of embryofetal toxicity or teratogenicity when fed to rats at 160x human ophthalmic dose.
| Average retention time on the cornea is 4 hours. |
Remove contact lenses prior to use; reinsert 30 minutes following administration. |